Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Feb;20(1):41-7.
doi: 10.1016/j.bjid.2015.09.011. Epub 2015 Nov 25.

Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients

Nafees Ahmad  1 , Arshad Javaid  2 , Syed Azhar Syed Sulaiman  3 , Long Chiau Ming  4 , Izaz Ahmad  5 , Amer Hayat Khan  3
Affiliations

Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients

Nafees Ahmad et al. Braz J Infect Dis. 2016 Jan-Feb.

Abstract

Background: Fluoroquinolones are the backbone of multidrug resistant tuberculosis treatment regimens. Despite the high burden of multidrug resistant tuberculosis in the country, little is known about drug resistance patterns, prevalence, and predictors of fluoroquinolones resistance among multidrug resistant tuberculosis patients from Pakistan.

Objective: To evaluate drug resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients.

Methods: This was a cross-sectional study conducted at a programmatic management unit of drug resistant tuberculosis, Lady Reading Hospital Peshawar, Pakistan. Two hundred and forty-three newly diagnosed multidrug resistant tuberculosis patients consecutively enrolled for treatment at study site from January 1, 2012 to July 28, 2013 were included in the study. A standardized data collection form was used to collect patients' socio-demographic, microbiological, and clinical data. SPSS 16 was used for data analysis.

Results: High degree of drug resistance (median 5 drugs, range 2-8) was observed. High proportion of patients was resistant to all five first-line anti-tuberculosis drugs (62.6%), and more than half were resistant to second line drugs (55.1%). The majority of the patients were ofloxacin resistant (52.7%). Upon multivariate analysis previous tuberculosis treatment at private (OR=1.953, p=0.034) and public private mix (OR=2.824, p=0.046) sectors were predictors of ofloxacin resistance.

Conclusion: The high degree of drug resistance observed, particularly to fluoroquinolones, is alarming. We recommend the adoption of more restrictive policies to control non-prescription sale of fluoroquinolones, its rational use by physicians, and training doctors in both private and public-private mix sectors to prevent further increase in fluoroquinolones resistant Mycobacterium tuberculosis strains.

Keywords: Fluoroquinolones; MDR-TB; Private; Resistance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Inclusion and exclusion of study patients. MDR-TB, multidrug resistant tuberculosis; XDR-TB, extensive drug resistant tuberculosis.
See this image and copyright information in PMC

References

    1. Gay J., DeYoung D., Roberts G. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother. 1984;26:94–96. - PMC - PubMed
    1. Falzon D., Gandhi N., Migliori G.B., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J. 2013;42:156–168. - PMC - PubMed
    1. Johnston J.C., Shahidi N.C., Sadatsafavi M., Fitzgerald J.M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4:e6914. - PMC - PubMed
    1. Kurbatova E.V., Taylor A., Gammino V.M., et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92:397–403. - PMC - PubMed
    1. Leimane V., Riekstina V., Holtz T.H., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318–326. - PubMed

LinkOut - more resources